Related Experiment Video
Updated: Apr 29, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Efficacy of ruxolitinib for myelofibrosis
Fabio P S Santos1, Srdan Verstovsek
1Hospital Israelita Albert Einstein, Hematology and Oncology Center , São Paulo, SP , Brazil.
Introduction:
The discovery of the activating JAK2 V617F mutation in patients with myelofibrosis (MF) led to the development of JAK2 inhibitors. The first such inhibitor to enter clinical trials was ruxolitinib . This review summarizes preclinical and clinical data of ruxolitinib in MF.
Areas Covered:
A literature search through Medline employing the terms 'ruxolitinib,' 'INCB018424' and 'myelofibrosis' was undertaken. The results from Phase I/II studies in patients with MF showed that ruxolitinib led to durable improvements in splenomegaly, and symptoms associated with MF. Two Phase III trials have compared ruxolitinib against placebo and best available therapy, and in both studies ruxolitinib demonstrated superior rates of spleen control and symptom improvement, and additional analysis demonstrated a survival benefit with ruxolitinib treatment. The main toxicities seen with ruxolitinib are cytopenias, which are managed with dose adjustments. Recent reports documented sporadic cases of immunosuppression-related infections. Ruxolitinib is the first drug ever approved for the therapy of patients with MF.
Expert Opinion:
Understanding the factors that predict the rate and duration of response to ruxolitinib would improve our ability to manage patients treated with this medication. Clinical trials combining ruxolitinib with novel compounds that are also active in MF will further improve therapy for this disease.
Insights
Ruxolitinib, a JAK2 inhibitor, effectively treats myelofibrosis (MF) by reducing spleen size and symptoms. It offers a survival benefit, with manageable side effects like cytopenias.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- The JAK2 V617F mutation discovery spurred JAK2 inhibitor development for myelofibrosis (MF).
- Ruxolitinib was the first JAK2 inhibitor investigated in clinical trials for MF.
- This review synthesizes preclinical and clinical evidence for ruxolitinib in MF treatment.
Purpose of the Study:
- To review preclinical and clinical data on ruxolitinib for myelofibrosis (MF).
- To summarize the efficacy and safety of ruxolitinib in MF patients.
Main Methods:
- Literature search of Medline using terms 'ruxolitinib,' 'INCB018424,' and 'myelofibrosis.'
- Analysis of Phase I/II and Phase III clinical trial data comparing ruxolitinib to placebo and best available therapy.
Main Results:
- Ruxolitinib demonstrated durable improvements in splenomegaly and MF-associated symptoms.
- Phase III trials confirmed superior spleen control and symptom improvement with ruxolitinib.
- Ruxolitinib treatment showed a survival benefit; main toxicities include manageable cytopenias.
Conclusions:
- Predicting response to ruxolitinib can optimize patient management.
- Combining ruxolitinib with novel agents may further enhance MF therapy.
